IRIS
MONDELLI, MARIO UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.769
AS - Asia 8.136
EU - Europa 6.543
SA - Sud America 1.216
AF - Africa 236
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 12
AN - Antartide 1
Totale 26.931
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.525
CN - Cina 3.966
SG - Singapore 1.799
IE - Irlanda 1.389
BR - Brasile 917
UA - Ucraina 887
HK - Hong Kong 873
DE - Germania 802
FI - Finlandia 731
VN - Vietnam 707
IT - Italia 653
RU - Federazione Russa 642
FR - Francia 453
SE - Svezia 381
GB - Regno Unito 329
IN - India 156
CA - Canada 140
BD - Bangladesh 132
AR - Argentina 104
ZA - Sudafrica 85
IQ - Iraq 69
JP - Giappone 63
MX - Messico 62
EC - Ecuador 54
ID - Indonesia 48
PL - Polonia 43
CO - Colombia 38
TR - Turchia 38
NL - Olanda 36
PK - Pakistan 35
VE - Venezuela 34
AT - Austria 32
ES - Italia 31
MA - Marocco 28
SA - Arabia Saudita 28
UZ - Uzbekistan 26
CZ - Repubblica Ceca 24
TN - Tunisia 20
CL - Cile 19
DZ - Algeria 19
BE - Belgio 18
KE - Kenya 18
EG - Egitto 17
PY - Paraguay 17
PH - Filippine 16
IR - Iran 15
KZ - Kazakistan 14
MY - Malesia 14
AU - Australia 13
JO - Giordania 13
AZ - Azerbaigian 12
CH - Svizzera 12
NP - Nepal 12
PE - Perù 12
IL - Israele 11
KG - Kirghizistan 11
UY - Uruguay 11
LT - Lituania 10
BH - Bahrain 9
OM - Oman 9
TH - Thailandia 9
BO - Bolivia 7
GA - Gabon 7
NI - Nicaragua 7
AE - Emirati Arabi Uniti 6
AL - Albania 6
BG - Bulgaria 6
CR - Costa Rica 6
EE - Estonia 6
EU - Europa 6
GR - Grecia 6
LB - Libano 6
SN - Senegal 6
DO - Repubblica Dominicana 5
ET - Etiopia 5
HR - Croazia 5
KR - Corea 5
PS - Palestinian Territory 5
CI - Costa d'Avorio 4
HU - Ungheria 4
JM - Giamaica 4
KW - Kuwait 4
LV - Lettonia 4
MU - Mauritius 4
PR - Porto Rico 4
QA - Qatar 4
RO - Romania 4
SI - Slovenia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AM - Armenia 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
BB - Barbados 3
CY - Cipro 3
DK - Danimarca 3
GT - Guatemala 3
LU - Lussemburgo 3
MD - Moldavia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
Totale 26.867
Salva come PNG Salva come JPEG
Città #
Chandler 1.439
Dublin 1.385
Jacksonville 1.192
Ashburn 1.141
San Jose 1.123
Singapore 911
Nanjing 904
Hong Kong 863
Dallas 722
Beijing 524
Boardman 488
Nanchang 380
Princeton 322
Lawrence 289
Lauterbourg 284
Wilmington 272
Shenyang 254
Hebei 237
Changsha 231
Ho Chi Minh City 221
Jiaxing 220
Los Angeles 198
Helsinki 186
Tianjin 174
Milan 168
Medford 159
Hanoi 158
Munich 156
Hangzhou 139
New York 134
Buffalo 123
Council Bluffs 123
Redondo Beach 122
Moscow 120
Ann Arbor 99
Shanghai 93
São Paulo 81
Pavia 77
Toronto 75
Verona 69
Orem 67
Tokyo 61
Turku 60
Woodbridge 60
Johannesburg 59
Norwalk 57
Santa Clara 53
Seattle 50
Da Nang 42
Brooklyn 37
The Dalles 37
Chicago 36
Warsaw 36
Frankfurt am Main 35
Zhengzhou 33
Baghdad 31
Chennai 31
Nuremberg 31
Guangzhou 30
Jinan 30
Denver 29
Des Moines 29
Haiphong 29
Montreal 27
Quito 27
Rio de Janeiro 27
Fairfield 26
London 24
Boston 23
Falkenstein 23
Houston 23
Tashkent 23
Dong Ket 22
Phoenix 22
San Francisco 22
Brasília 20
Columbus 20
Falls Church 20
Manchester 20
Pune 20
Auburn Hills 19
Kunming 19
Curitiba 18
Stockholm 18
Amsterdam 17
Brussels 17
Dhaka 17
Lahore 17
Nairobi 17
Washington 17
Atlanta 16
Belo Horizonte 16
Guayaquil 15
Mexico City 15
Ningbo 15
Biên Hòa 14
Piscataway 14
Vienna 14
Bergamo 13
Berlin 13
Totale 17.529
Salva come PNG Salva come JPEG
Nome #
MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma 316
Mapping the human genetic architecture of COVID-19 302
Mapping the human genetic architecture of COVID-19 194
A first update on mapping the human genetic architecture of COVID-19 193
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 149
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 140
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 138
Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy 137
Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020 134
Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs 132
Cross-reactive antibodies to hypervariable region 1 (HVR1) of the hepatitis C virus E2/gp70 glycoprotein 128
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 126
Emergency Department and Out-of-Hospital Emergency System (112—AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre 125
Alfa-interferon enhances non-T cell cytotoxicity fo rautologous hepatocytes in acute and chronic HBV infection 119
COVID vaccination and asthma exacerbation: might there be a link? 119
Antibody responses to the hepatitis C virus (HCV) E2 protein: relationship to viraemia and prevalence in anti-HCV seronegative subjects. 118
CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. 118
A longitudinal analysis of hepatitis C virus replication following liver transplantation 118
Immunophatogenesis of viral hepatitis 117
A survey of hepatitis C virus infection in haemodialysis patients over a 7-years follow-up. 116
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 116
Codon 72 polymorphisms of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients 115
Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. 115
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 115
A major conformational B cell epitope on the HCV NS3 region defined by a human monoclonal antibody 114
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 114
Acute hepatitis C: diagnosis and management. 113
Detection of HTLV-III specific IgG in the CSF from patient with AIDS and encephalitis. 113
Hepatitis B virus structure and biology. 112
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 111
A human monoclonal antibody specific for a conserved epitope within the HCV protein 111
Accuracy of the ElastPQ Technique for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C: a "Real Life" Single Center Study 111
Does the immune response play a role in the pathogenesis of chronic liver disease? 109
GB virus C infection in patients treated for childhood acute lymphoblastic leukemia 109
Recombinant human antibodies specific for hepatitis C virus proteins 109
Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in haemodialysis patients. 108
Deficient natural killer cell NKp30-mediated function and altered NCR3 splice variants in hepatocellular carcinoma 108
Antibody-negative chronic hepatitis C virus infection in immunocompetent children 107
A phase II, single arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection 107
NKG2D and its ligands: key to immunotherapy of liver cancer? 107
Adenoviral mediated expression of anti-HCV NS3 single-chain Fv (sFv) antibody reduces HCV RNA in infected hepatocytes 107
Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing? 107
High Frequencies of Functional Virus-Specific CD4+ T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders 106
A human monoclonal antibody specific for the N-terminus of hepatitis C virus nucleocapsid protein 105
Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis 105
Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virus-induced activation 104
Dissociation between serum and liver hepatitis C virus RNA levels in patients coinfected with human immunodeficiency virus 104
Comparative evaluation of two serologic typing methods of hepatitis C virus 104
Absence of antibodies to human immunodeficiency virus in long-term institutionalized psychiatric patients. 104
Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre 104
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 104
Low prevalence of antibodies to the HCV envelope region in anti-HCV seronegative, HCV RNA positive patients 103
Clinical significance of hepatitis C virus genotypes. 102
Analysis of hepatitis C virus hypervariable region 1 sequence in cryoglobulinaemic patients and associated control 102
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. 101
Characterization of monoclonal antibodies (mAb) from mice immunized with HCV hypervariable region 1 (HVR1) mimotopes. 101
Association between class II allelles and protection or susceptibility to chronic hepatitis C 101
Comparative evaluation of two serological typing methods for hepatitis C virus 101
HCV genotype 1b is a major risk factor for the development of hepatocellular carcinoma (HCC) in cirrhotic patients: a prospective study 101
Clonality and specificity of cryoglobulins associated with HCV: pathophysiological implications 100
Molecular epidemiology of hepatitis C virus infection in intravenous drug users. 99
Significance of hepatic expression of hepatitis C viral antigens in chronic hepatitis C 99
A human antibody specific for the hepatitis C virus core protein: expression in a bacterial system and characterization. 99
Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56brightNK cells 99
PD-L1 negatively regulates CD4+CD25+Foxp3+ tregs by limiting STAT-5 phosphrylation in patients chronically infected with HCV 99
Modelling liver fibrosis progression in chronic hepatitis C: a study of 563 patients with sequential liver biopsies 98
Defective cytotoxic function of intrahepatic natural killer cells in chronic hepatitis C virus infection 98
HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy 98
Defective DNAM-1 Dependent Cytotoxicity in Hepatocellular Carcinoma-Infiltrating NK Cells 97
Impaired intratumoral natural killer cell function in head and neck carcinoma 97
Is the natural history of hepatitis C virus carriers with normal aminotransferase really bening? 97
Polymorphisms of microsomal epoxyde hydrolase gene and severity of HCV-related liver disease. 97
B lymphocyte activation in chronic HCV infection: implications for autoimmune and lymphoproliferative disorders 97
Engagement of Siglec-7 receptor induces a pro-inflammatory response selectively in monocytes 97
Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. 96
Epidemiology of HCV genotypes and risk of cirrhosis in apulia: a population-based case-control study 96
The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort 96
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 96
HLA class II alleles confer protection or susceptibility to chronic hepatitis C 95
Detection of genomic and minus strand C virus RNA in the liver of chronic hepatitis C patients by strand-specific semi-quantitative RT-PCR 95
The impact of viral genotype on the natural history of HCV-induced cirrhosis: a prospective study 95
EASL Clinical Practice Guidelines: management of hepatitis C virus infection 95
ANTIBODY RESPONSES TO HEPATITIS C VIRUS HYPERVARIABLE REGION 1: EVIDENCE FOR CROSS-REACTIVITY AND IMMUNE-MEDIATED SEQUENCE VARIATION. 95
T-cell cytotoxicity and circulating T-cell subsets in chronic HBV infection 95
Mutations at position 385 within the hypervariable region 1 (HVR1) of the hepatitis C virus (HCV) are rare and not rescricted to patients with cryoglobulinemia 94
A human monoclonal antibody against hepatitis B surface antigen with potent neutralizing activity 94
Assessment of HCV RNA clearance under combination therapy for HCV genotype 1: performance of the transcription-mediated amplification (TMA) assay. 93
Viral and host immune regulatory mechanisms in HCV infection 93
Characterization of cryoglobulins from patients with type II mixed cryoglobulinaemia associated with HCV 93
Interferon-alpha enhances non-specific cytotoxicity for autologous hepatocytes in acute and chronic hepatitis B virus infection 93
Lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection. 93
Optimization for the detection of hepatitis C virus (HCV) antigens in the liver 93
Genetic mechanisms of critical illness in COVID-19 93
Relationship between expression of HBV antigenes in isolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic HBV infection. 92
Direct-acting antivirals cure innate immunity in chronic hepatitis C 92
Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST expert opinion meeting 92
Caratterizzazione delle IgG presenti nel crioprecipitato di pazienti con crioglobulinemia mista di tipo II associata ad infezione da HCV 92
HCV viremia in hemodialysis patients 91
SIGNIFICANCE OF THE IMMUNE RESPONSE TO A MAJOR, CONFORMATIONAL B CELL EPITOPE ON THE HEPATITIS C VIRUS NS3 REGION DEFINED BY A HUMAN MONOCLONAL ANTIBODY 91
Hypervariable region 1 (HVR1) of HCV: immunological decoy or biologically relevant domain? 90
Totale 11.133
Salva come PNG Salva come JPEG
Categoria #
all - tutte 119.191
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 119.191
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202181 0 0 0 0 0 0 0 0 0 0 0 81
2021/20221.212 45 11 50 33 16 71 12 83 70 25 197 599
2022/20234.267 515 232 30 468 432 453 2 225 1.648 16 201 45
2023/20241.683 150 246 46 116 162 375 47 363 7 40 53 78
2024/20253.924 90 398 133 162 61 114 179 290 947 103 427 1.020
2025/20269.026 683 803 1.139 1.056 963 374 1.656 336 786 678 338 214
Totale 27.462